Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,deferredLongTermAssetCharges,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,currency,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,ILU.DE,3891000000.0,146000000,197000000,,169000000,,147000000,374000000,770000000,193000000,193000000,,-19000000,,,,22000000,1093000000,900000000,323000000,-24000000,,147000000,147000000,134000000.0,3914000000.0,3833000000.0,4922000000.0,319000000.0,8755000000.0,2000000.0,4870000000.0,229000000.0,897000000.0,-3864000000.0,185000000.0,4433000000.0,1268000000.0,488000000.0,8000000.0,1444000000.0,5642000000.0,453000000.0,197000000.0,517000000.0,1672000000.0,364000000.0,178000000.0,,1366000000,-8000000,1376000000,961000000,968000000,101000000,31000000,2623000000,-24000000,-3000000,282000000,48000000,52000000,8000000,-39000000,15000000,-42000000,4374000000.0,en-US,US,EQUITY,False,Delayed Quote,-0.6056003,393.9 - 393.9,396.3,390.7,392.9,finmb_29753,XETRA,"Illumina, Inc.",USD,91,190,182.9,0.8668246,211.0 - 446.1,-52.200012,-0.11701415,211.0,446.1,1619539500,1635332340,1635768000,109.843834,3.586,EUR,2,33.712,414.30286,-20.402863,-0.04924625,368.35706,25.542938,0.069342874,57509400576,11.684266,15,Europe/Berlin,CEST,7200000,GER,0,False,False,393.9,1630566245,-2.399994,393.9,393.9,393.9,5,"ILLUMINA INC.  DL-,01",de_market,REGULAR,0.94,,,446.1,211.0,414.3,368.36,91,190,146M,,145.52M,0.26%,92.73%,,,,,,,,,,,0.00%,,,,,"Jan 03, 2021","Apr 04, 2021",18.14%,16.04%,4.35%,13.18%,3.47B,23.67,27.20%,2.23B,748M,630M,3.59,-15.00%,4.63B,31.71,2.88B,58.45,4.45,33.71,1.08B,772.5M,Value,92122,Healthcare,7800,8,4,"Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",San Diego,858 202 4500,CA,6,1609372800,1622505600,2,United States,http://www.illumina.com,86400,6,5200 Illumina Way,858 202 4545,Diagnostics & Research
t-1,ILU.DE,3655000000.0,146000000,126000000,,299000000,,257000000,373000000,637000000,131000000,131000000,,-16000000,,,,42000000,953000000,822000000,316000000,168000000,,257000000,257000000,142000000.0,3815000000.0,2891000000.0,4694000000.0,267000000.0,7585000000.0,2000000.0,4723000000.0,303000000.0,897000000.0,-3846000000.0,191000000.0,1810000000.0,1244000000.0,511000000.0,2000000.0,1454000000.0,4483000000.0,418000000.0,1662000000.0,487000000.0,673000000.0,372000000.0,192000000.0,20000000.0,28000000,42000000,-34000000,961000000,-331000000,37000000,31000000,49000000,-331000000,8000000,406000000,50000000,52000000,44000000,-19000000,-16000000,-62000000,3239000000.0,en-US,US,EQUITY,False,Delayed Quote,-0.6056003,393.9 - 393.9,396.3,390.7,392.9,finmb_29753,XETRA,"Illumina, Inc.",USD,91,190,182.9,0.8668246,211.0 - 446.1,-52.200012,-0.11701415,211.0,446.1,1619539500,1635332340,1635768000,109.843834,3.586,EUR,2,33.712,414.30286,-20.402863,-0.04924625,368.35706,25.542938,0.069342874,57509400576,11.684266,15,Europe/Berlin,CEST,7200000,GER,0,False,False,393.9,1630566245,-2.399994,393.9,393.9,393.9,5,"ILLUMINA INC.  DL-,01",de_market,REGULAR,0.94,,,446.1,211.0,414.3,368.36,91,190,146M,,145.52M,0.26%,92.73%,,,,,,,,,,,0.00%,,,,,"Jan 03, 2021","Apr 04, 2021",18.14%,16.04%,4.35%,13.18%,3.47B,23.67,27.20%,2.23B,748M,630M,3.59,-15.00%,4.63B,31.71,2.88B,58.45,4.45,33.71,1.08B,772.5M,Value,92122,Healthcare,7800,8,4,"Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",San Diego,858 202 4500,CA,6,1609372800,1622505600,2,United States,http://www.illumina.com,86400,6,5200 Illumina Way,858 202 4545,Diagnostics & Research
t-2,ILU.DE,3654000000.0,146000000,172000000,,215000000,,179000000,217000000,533000000,137000000,137000000,,-11000000,,,,36000000,794000000,657000000,261000000,78000000,,179000000,179000000,149000000.0,3737000000.0,2704000000.0,4700000000.0,210000000.0,7404000000.0,2000000.0,4466000000.0,245000000.0,897000000.0,-3505000000.0,179000000.0,1761000000.0,1115000000.0,507000000.0,12000000.0,1455000000.0,4329000000.0,395000000.0,1563000000.0,464000000.0,666000000.0,415000000.0,156000000.0,19000000.0,-14000000,11000000,-65000000,961000000,-101000000,-43000000,27000000,-9000000,-128000000,4000000,153000000,47000000,52000000,19000000,-82000000,12000000,-48000000,3214000000.0,en-US,US,EQUITY,False,Delayed Quote,-0.6056003,393.9 - 393.9,396.3,390.7,392.9,finmb_29753,XETRA,"Illumina, Inc.",USD,91,190,182.9,0.8668246,211.0 - 446.1,-52.200012,-0.11701415,211.0,446.1,1619539500,1635332340,1635768000,109.843834,3.586,EUR,2,33.712,414.30286,-20.402863,-0.04924625,368.35706,25.542938,0.069342874,57509400576,11.684266,15,Europe/Berlin,CEST,7200000,GER,0,False,False,393.9,1630566245,-2.399994,393.9,393.9,393.9,5,"ILLUMINA INC.  DL-,01",de_market,REGULAR,0.94,,,446.1,211.0,414.3,368.36,91,190,146M,,145.52M,0.26%,92.73%,,,,,,,,,,,0.00%,,,,,"Jan 03, 2021","Apr 04, 2021",18.14%,16.04%,4.35%,13.18%,3.47B,23.67,27.20%,2.23B,748M,630M,3.59,-15.00%,4.63B,31.71,2.88B,58.45,4.45,33.71,1.08B,772.5M,Value,92122,Healthcare,7800,8,4,"Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",San Diego,858 202 4500,CA,6,1609372800,1622505600,2,United States,http://www.illumina.com,86400,6,5200 Illumina Way,858 202 4545,Diagnostics & Research
t-3,ILU.DE,3513000000.0,146000000,155000000,,165000000,,47000000,177000000,435000000,96000000,96000000,,-11000000,,,,118000000,633000000,537000000,198000000,69000000,,47000000,47000000,156000000.0,3649000000.0,2685000000.0,4563000000.0,207000000.0,7248000000.0,2000000.0,4287000000.0,230000000.0,894000000.0,-3375000000.0,181000000.0,1770000000.0,1115000000.0,503000000.0,14000000.0,1439000000.0,4194000000.0,384000000.0,1498000000.0,385000000.0,659000000.0,435000000.0,135000000.0,13000000.0,-186000000,3000000,-320000000,961000000,-143000000,67000000,2000000,-221000000,-145000000,2000000,240000000,46000000,52000000,-51000000,91000000,28000000,-39000000,3079000000.0,en-US,US,EQUITY,False,Delayed Quote,-0.6056003,393.9 - 393.9,396.3,390.7,392.9,finmb_29753,XETRA,"Illumina, Inc.",USD,91,190,182.9,0.8668246,211.0 - 446.1,-52.200012,-0.11701415,211.0,446.1,1619539500,1635332340,1635768000,109.843834,3.586,EUR,2,33.712,414.30286,-20.402863,-0.04924625,368.35706,25.542938,0.069342874,57509400576,11.684266,15,Europe/Berlin,CEST,7200000,GER,0,False,False,393.9,1630566245,-2.399994,393.9,393.9,393.9,5,"ILLUMINA INC.  DL-,01",de_market,REGULAR,0.94,,,446.1,211.0,414.3,368.36,91,190,146M,,145.52M,0.26%,92.73%,,,,,,,,,,,0.00%,,,,,"Jan 03, 2021","Apr 04, 2021",18.14%,16.04%,4.35%,13.18%,3.47B,23.67,27.20%,2.23B,748M,630M,3.59,-15.00%,4.63B,31.71,2.88B,58.45,4.45,33.71,1.08B,772.5M,Value,92122,Healthcare,7800,8,4,"Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.",San Diego,858 202 4500,CA,6,1609372800,1622505600,2,United States,http://www.illumina.com,86400,6,5200 Illumina Way,858 202 4545,Diagnostics & Research
